Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

View/ Open
Date
2022-03-04ICR Author
Author
Gillison, ML
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Licitra, L
Harrington, KJ
Kasper, S
Vokes, EE
Even, C
Worden, F
Saba, NF
Docampo, LCI
Haddad, R
Rordorf, T
Kiyota, N
Tahara, M
Jayaprakash, V
Wei, L
Ferris, RL
Type
Journal Article
Metadata
Show full item recordCollections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
clinical trial
squamous cell carcinoma of head and neck
nivolumab
immunotherapy
SQUAMOUS-CELL CARCINOMA
INVESTIGATORS CHOICE
OPEN-LABEL
CETUXIMAB
CHEMOTHERAPY
PLATINUM
Research team
Targeted Therapy
Language
eng
Date accepted
2021-11-30
License start date
2022-03-04
Citation
ONCOLOGIST, 2022, 27 (2), pp. E194 - E198 (5)
Publisher
OXFORD UNIV PRESS